Oleanolic acid protects against diabetic cardiomyopathy via modulation of the nuclear factor erythroid 2 and insulin signaling pathways
| Autor: | Tianyi Li, Su‑Fang Chen, Weifang Li, Hua Li, Ming Feng, Peng Wang |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Cancer Research
medicine.medical_specialty medicine.medical_treatment 030204 cardiovascular system & hematology 03 medical and health sciences Glycogen phosphorylase chemistry.chemical_compound 0302 clinical medicine Immunology and Microbiology (miscellaneous) Internal medicine Diabetic cardiomyopathy Diabetes mellitus medicine Oleanolic acid biology Insulin Articles General Medicine medicine.disease Streptozotocin Heme oxygenase Insulin receptor Endocrinology chemistry 030220 oncology & carcinogenesis biology.protein medicine.drug |
| Zdroj: | Experimental and Therapeutic Medicine. 14:848-854 |
| ISSN: | 1792-1015 1792-0981 |
| Popis: | Oleanolic acid (OL) is a pentacyclic triterpene compound used for the treatment of hepatitis, liver fibrosis and liver cirrhosis. In China, there is no published research on the effect or biological utilization of OL on liver diseases. The aim of the present study was to investigate the protective effects of OL against diabetic cardiomyopathy and its possible mechanism. A rat model of diabetes was established using streptozotocin and the effect of OL on diabetic cardiomyopathy (DCM) was evaluated. The results demonstrated that OL significantly reversed the DCM-induced changes to body weight, heart rate, echocardiography and hemodynamics, phosphorylated-glycogen synthase (GS) and glycogen phosphorylase (GP) activity in diabetic rats (all P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|